Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2021-05 Issue: Volume: Page:
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Spertus John A,Fine Jennifer T,Elliott Perry,Ho Carolyn Y,Olivotto Iacopo,Saberi Sara,Li Wanying,Dolan Chantal,Reaney Matthew,Sehnert Amy J,Jacoby Daniel

Publisher

Elsevier BV

Subject

General Medicine

Reference36 articles.

1. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy;Marian;Circ Res,2017

2. Clinical Course and management of hypertrophic cardiomyopathy;Maron;N Engl J Med,2018

3. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life;Zaiser;J Patient Rep Outcomes,2020

4. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC);Elliott;Eur Heart J,2014

5. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines;Ommen;Circulation,2020

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapie der hypertrophen Kardiomyopathie;CardioVasc;2024-09

2. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy;Journal of the American College of Cardiology;2024-09

3. Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction;Journal of the American College of Cardiology;2024-09

4. Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM;JACC: Cardiovascular Imaging;2024-09

5. Ninerafaxstat in the Treatment of Diabetic Cardiomyopathy and Nonobstructive Hypertrophic Cardiomyopathy;Cardiology in Review;2024-08-28